
    
      This study is a 24-weeks, multicenter, randomized, double-blind, double- placebo, parallel
      controlled phase III trial being carried out in 23 centers around China. The study population
      includes mild to moderate VaD patients (planned a total of 630) aged 45-85 in both gender.
      Participants will be randomly allocated to TZK (15g/d) and placebo identified to donepezil,
      donepezil (5mg/d) and placebo identified to TZK, or placebo identified to TZK and placebo
      identified to donepezil for a 24-weeks double-blind treatment period . The primary outcome
      measure is change from baseline in the Vascular Dementia Assessment Scale-Cognitive Subscale
      and Clinician's Interview-Based Impression of Change-Plus carer Interview. The secondary
      outcomes are changes from baseline in the Mini-Mental State Examination, Activity of Daily
      Living Scale, Clock Drawing Test, Trail Making Test and Neuropsychiatric Inventory. Safety is
      being assessed by observing side effects and adverse reaction during the entire treatment
      period. Statistical analysis will be conducted according to per-protocol population and
      intend-to-treat population and the safety will be analyzed in safety set.
    
  